Joshua J Crose, Arezou Crose, John T Ransom, Amy L Lightner
{"title":"Bone marrow mesenchymal stem cell-derived extracellular vesicle infusion for amyotrophic lateral sclerosis.","authors":"Joshua J Crose, Arezou Crose, John T Ransom, Amy L Lightner","doi":"10.1080/17582024.2024.2344396","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> In this pilot safety study, we hypothesized that a human bone marrow stem cell-derived extracellular vesicle (hBM-MSC EV) investigational product (IP) would be safe and exhibit potential efficacy in amyotrophic lateral sclerosis (ALS) patients.<b>Methods:</b> Ten ALS patients received two 10-ml intravenous infusions of the IP given 1 month apart and evaluated over 3 months.<b>Results:</b> There were no serious adverse events or adverse events related to the IP and 30% of subjects' ALS functional rating scale-revised (ALSFRS-R) scores did not decline.<b>Conclusion:</b> HBM-MSC EVs appear safe in ALS patients. This early investigation suggests a controlled study of EVs for the treatment of ALS is warranted.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"14 3-4","pages":"111-117"},"PeriodicalIF":2.3000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457643/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurodegenerative disease management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17582024.2024.2344396","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/28 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: In this pilot safety study, we hypothesized that a human bone marrow stem cell-derived extracellular vesicle (hBM-MSC EV) investigational product (IP) would be safe and exhibit potential efficacy in amyotrophic lateral sclerosis (ALS) patients.Methods: Ten ALS patients received two 10-ml intravenous infusions of the IP given 1 month apart and evaluated over 3 months.Results: There were no serious adverse events or adverse events related to the IP and 30% of subjects' ALS functional rating scale-revised (ALSFRS-R) scores did not decline.Conclusion: HBM-MSC EVs appear safe in ALS patients. This early investigation suggests a controlled study of EVs for the treatment of ALS is warranted.
背景：在这项安全性试验研究中，我们假设人骨髓干细胞衍生的细胞外囊泡(hBM-MSC EV)研究产品(IP)对肌萎缩性脊髓侧索硬化症(ALS)患者是安全的，并具有潜在疗效：10名ALS患者接受了两次10毫升的IP静脉注射，每次间隔1个月，并在3个月内进行评估：结果：没有发生与 IP 有关的严重不良事件或不良反应，30% 的受试者的 ALS 功能评分表（ALSFRS-R）评分没有下降：结论：HBM-间充质干细胞 EVs 对 ALS 患者似乎是安全的。结论：HBM-间充质干细胞对 ALS 患者似乎是安全的。这项早期调查表明，有必要对 EVs 治疗 ALS 进行对照研究。
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
